Can we teach how to discriminate between good & bad evidence? the GATE approach

Similar documents
GATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms

GATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms

GATE CAT Intervention RCT/Cohort Studies

GLOSSARY OF GENERAL TERMS

GATE CAT Diagnostic Test Accuracy Studies

Appendix 2 Quality assessment tools. Cochrane risk of bias tool for RCTs. Support for judgment

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Protocol Development: The Guiding Light of Any Clinical Study

Thursday, April 25, 13. Intervention Studies

Overview of Study Designs in Clinical Research

The comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.

Quantitative research Quiz Answers

Thursday, April 25, 13. Intervention Studies

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES

CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM

RANDOMIZED CLINICAL TRIALS. Study Designs. Randomized Clinical Trials (RCT) ASSIGN EXPOSURE Follow up Check for OUTCOME. Experimental studies

Outline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:

Controversies in Primary Care Pros and Cons of HRT on patients with CHD

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

EBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University

Appraising the Literature Overview of Study Designs

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

GATE CAT Case Control Studies

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

HARM. Definition modified from the IHI definition of Harm by the QUEST Harm Workgroup

Critical Appraisal of RCT

Study Designs in Epidemiology

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

Issues to Consider in the Design of Randomized Controlled Trials

No relevant financial relationships

Introduction to Evidence-Based Medicine

JAMA. 2011;305(24): Nora A. Kalagi, MSc

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

the standard deviation (SD) is a measure of how much dispersion exists from the mean SD = square root (variance)

INfluenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated heart failure

Menopausal hormone therapy currently has no evidence-based role for

Critical Appraisal. Dave Abbott Senior Medicines Information Pharmacist

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Study Designs. Randomized Clinical Trials (RCT) RCT: Example 1. RCT: Two by Two Table. Outcome. Exposure. Yes a b No c d

Health Studies 315. Clinical Epidemiology: Evidence of Risk and Harm

Objectives. Distinguish between primary and secondary studies. Discuss ways to assess methodological quality. Review limitations of all studies.

Antihypertensive Trial Design ALLHAT

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

FROM A QUESTION TO A PAPER

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern

Version No. 7 Date: July Please send comments or suggestions on this glossary to

Critical Appraisal Series

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Potential dangers of hormone replacement therapy in women at high risk

Updates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course

ACR OA Guideline Development Process Knee and Hip

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial

Clinical problems and choice of study designs

STUDY DESIGN. Jerrilyn A. Cambron, DC, PhD Department of Research. RE6002: Week 2. National University of Health Sciences

Clinical Research Design and Conduction

Evidence Based Medicine

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Systematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)

8/18/10. Disclosure. Objectives. A Pervasive Concern. Evidence Based Medicine, Family Physicians, and Knowledge Translation (KATIE)

exposure/intervention

CRITICALLY APPRAISED PAPER (CAP)

State of the art pharmacoepidemiological study designs for post-approval risk assessment

Systematic Reviews and Meta- Analysis in Kidney Transplantation

Is Lower Better for LDL or is there a Sweet Spot

Chapter 1 - Sampling and Experimental Design

Lipid Management 2013 Statin Benefit Groups

CONSORT 2010 Statement Annals Internal Medicine, 24 March History of CONSORT. CONSORT-Statement. Ji-Qian Fang. Inadequate reporting damages RCT

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

There is good evidence (Level 1a) to support the use of relaxation therapy for children and adolescents with headaches.

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN

Critical Appraisal of Evidence

Main objective of Epidemiology. Statistical Inference. Statistical Inference: Example. Statistical Inference: Example

Department of OUTCOMES RESEARCH

NUHS Evidence Based Practice I Journal Club. Date:

SESSION 3 11 AM 12:30 PM

Statistical Methods in Medical Research

Clinical Research Scientific Writing. K. A. Koram NMIMR

Systematic Reviews. Simon Gates 8 March 2007

Measures of Association

How to CRITICALLY APPRAISE

EBM, Study Design and Numbers. David Frankfurter, MD Professor OB/GYN The George Washington University

Evidence Based Medicine

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

aps/stone U0 d14 review d2 teacher notes 9/14/17 obj: review Opener: I have- who has

Lecture 4. Analytical Interventional Studies

Critical Appraisal of Evidence A Focus on Intervention/Treatment Studies

What could a public health strategy for weight loss look like? Paul Aveyard Professor of behavioural medicine

Estrogen and progestogen therapy in postmenopausal women

Atherosclerotic Disease Risk Score

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

The Cardiac Arrythmia Suppression Trial

Journal Club Handbook

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Generalizing the right question, which is?

Blood pressure treatment target in diabetes. Should it be <130 mmhg?

Glossary of Practical Epidemiology Concepts

Meta-analyses: analyses:

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Transcription:

Can we teach how to discriminate between good & bad evidence? in 20 minutes! the GATE approach Rod Jackson June 2010

GATE: a Graphic Appraisal Tool for Epidemiology A picture, 2 acronyms & 2 formulas

A picture: the GATE frame the shape of every epidemiological study

The ECT acronym: the 5 parts of every epidemiological study articipants Exposure Group E C Comparison Group Time T utcomes All epidemiological studies can be hung on the GATE frame

2 formulas: study analyses 1. ccurrence of disease = Numerator Denominator Time D N 2. Random error (95% Confidence Interval) = 1.96 x Standard Error

The RAMMbo* acronym: assessing study bias Recruitment E C E C Allocation Maintenance T T Measurement of outcomes blind or objective * aul Glasziou

GATE frame picture & ECT acronym articipants Exposure Group E C Comparison Group Time T utcomes Describe a study s design by hanging ECT on the frame

articipants Study Setting Eligible articipants articipants

Exposure & Comparison Groups Exposure or Intervention Group (EG) EG CG Comparison or Control Group (CG)

utcomes () Dis-ease yes no a c b d utcomes ()

Time (T) incidence T prevalence

Study design: GATE frame & ECT articipants Exposure Group E C Comparison Group utcomes Time T Every epidemiological study hangs on the GATE frame

HERS example JAMA 1998;280:605-613 articipants Study Setting: outpatients & community, 20 US centres Eligible articipants: post-menopausal women with CHD, < 80 years, with intact uterus articipants: 2763, mean age 66.7 years

Exposure & Comparison Groups Exposure or Intervention Group (EG): 0.625mg conj equine estrogen& 2.5mg progesterone in 1 tablet 1380 1383 1353 1351 Comparison or Control Group (CG): placebo tablet of identical appearance

utcomes () Dis-ease : nonfatal MI or CHD death yes no a= 172 c b= 176 d utcomes ()

Time (T) utcome: non-fatal MI & CHD death T= 4.1 years (av. follow-up) incidence

Time (T) utcome: lipid levels T = at 1 year prevalence

2 formulas: study analyses 1. ccurrence of disease = Numerator Denominator Time D N 2. Random error (95% Confidence Interval) = 1.96 x Standard Error

All epidemiological studies involve measuring the CCURRENCE of disease ccurrence = Numerator Denominator D Denominator (articipants) = N D N Numerator (utcomes)

GATE study analyses verall Denominator Denominator 1: Denominator 2: Exposure EG CG Comparison Group Group (EG) (CG) Numerator 1: a a c b d Numerator 2: b Describe a study s analyses by hanging the numbers on the frame

ccurrence = N D Denominator 1: Exposure Group EG EG CG Denominator 2: Comparison Group CG Numerator 1: a a c b d Numerator 2: b Exposure Group ccurrence: EG = a EG Comparison Group ccurrence: CG = b CG

Calculate EG & CG for the outcome MI & CHD death in HERS Denominator 1: Exposure Group EG = 1380 EG CG Denominator 2: Comparison Group CG = 1383 Numerator 1: a = 172 a c b d Numerator 2: b = 176 EG = 172/1380 = 12.46/100 people in 5yrs CG = 176/1383 = 12.73/100 people in 5 yrs

Describing differences between occurrences Relative difference or Relative Risk = EG CG Absolute Difference or Risk Difference = EG - CG Number Needed To Treat (NNT) = 1 RD

Analyses it s all about EG & CG

The RAMMbo acronym: assessing study bias Recruitment E C E C Allocation Maintenance T T Measurement of outcomes blind or objective

E C RAMMbo appropriate Recruitment processes? Study setting & eligibility criteria well described? e.g. Recruit random/representative sample R consecutive eligiblesr volunteers from advertisements articipants representative of eligibles? rognostic/risk profile appropriate? T

RAMBbo: A is for Allocation RCT: Allocate randomly by investigators (e.g drugs) EG CG Cohort: Allocate by measurement (e.g. smoking) EG CG T T

T EG CG RAMMbo good Maintenance? did most participants remain in allocated groups (EG & CG) articipants &/or investigators blind to exposure (and comparison exposure)? Compliance high & similar in EG &CG? Contamination low & similar in EG &CG? Co-interventions low & similar in EG &CG? Completeness of follow-up high & similar in EG &CG?

A RAMMbo Measurement of outcomes blind orobjective? EG CG T If outcome measurements not bjective (eg. automated or definitive) were investigators blind to exposure (and comparison exposure)

The 4 (GATE) study biases Recruitment bias Allocation bias E C Maintenance bias T Measurement (of outcomes) bias

2 formulas: study analyses 1. ccurrence of disease = Numerator Denominator Time D N 2. Random error (95% Confidence Interval) = 1.96 x Standard Error

Excel CATs& paper Gate-lites There is a GATE for every study design www.epiq.co.nz

Including SRs & meta-analyses (the 3 rd acronym!) Find appropriate studies? Appraise selected studies? Include only valid studies? Total-up (synthesise) appropriately? Heterogeneity adequated addressed?